vs
CoStar Group（CSGP）与EXACT SCIENCES CORP（EXAS）财务数据对比。点击上方公司名可切换其他公司
CoStar Group的季度营收约是EXACT SCIENCES CORP的1.0倍（$899.9M vs $878.4M），CoStar Group净利率更高（5.2% vs -9.8%，领先15.0%），CoStar Group同比增速更快（26.9% vs 23.1%），EXACT SCIENCES CORP自由现金流更多（$120.4M vs $101.3M），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs 17.1%）
CoStar Group是1987年成立的美国商业地产服务商，总部位于弗吉尼亚州阿灵顿，业务覆盖北美、欧洲地区，为商业地产行业提供信息、分析及营销解决方案，旗下运营CoStar线上数据库、新闻网站及Apartments.com、Homes.com等多个线上平台。
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
CSGP vs EXAS — 直观对比
营收规模更大
CSGP
是对方的1.0倍
$878.4M
营收增速更快
CSGP
高出3.7%
23.1%
净利率更高
CSGP
高出15.0%
-9.8%
自由现金流更多
EXAS
多$19.1M
$101.3M
两年增速更快
EXAS
近两年复合增速
17.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $899.9M | $878.4M |
| 净利润 | $46.5M | $-86.0M |
| 毛利率 | 78.6% | 70.1% |
| 营业利润率 | 5.5% | -9.4% |
| 净利率 | 5.2% | -9.8% |
| 营收同比 | 26.9% | 23.1% |
| 净利润同比 | -22.2% | 90.1% |
| 每股收益（稀释后） | $0.12 | $-0.45 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CSGPEXAS
| Q4 25 | $899.9M | $878.4M | ||
| Q3 25 | $833.6M | $850.7M | ||
| Q2 25 | $781.3M | $811.1M | ||
| Q1 25 | $732.2M | $706.8M | ||
| Q4 24 | $709.4M | $713.4M | ||
| Q3 24 | $692.6M | $708.7M | ||
| Q2 24 | $677.8M | $699.3M | ||
| Q1 24 | $656.4M | $637.5M |
净利润CSGPEXAS
| Q4 25 | $46.5M | $-86.0M | ||
| Q3 25 | $-30.9M | $-19.6M | ||
| Q2 25 | $6.2M | $-1.2M | ||
| Q1 25 | $-14.8M | $-101.2M | ||
| Q4 24 | $59.8M | $-864.6M | ||
| Q3 24 | $53.0M | $-38.2M | ||
| Q2 24 | $19.2M | $-15.8M | ||
| Q1 24 | $6.7M | $-110.2M |
毛利率CSGPEXAS
| Q4 25 | 78.6% | 70.1% | ||
| Q3 25 | 79.3% | 68.6% | ||
| Q2 25 | 78.5% | 69.3% | ||
| Q1 25 | 79.1% | 70.8% | ||
| Q4 24 | 80.1% | 69.0% | ||
| Q3 24 | 79.7% | 69.4% | ||
| Q2 24 | 80.0% | 69.8% | ||
| Q1 24 | 78.5% | 70.0% |
营业利润率CSGPEXAS
| Q4 25 | 5.5% | -9.4% | ||
| Q3 25 | -6.1% | -3.0% | ||
| Q2 25 | -3.5% | -0.3% | ||
| Q1 25 | -5.8% | -13.6% | ||
| Q4 24 | 5.6% | -122.8% | ||
| Q3 24 | 3.4% | -5.6% | ||
| Q2 24 | -2.4% | -3.8% | ||
| Q1 24 | -6.5% | -16.7% |
净利率CSGPEXAS
| Q4 25 | 5.2% | -9.8% | ||
| Q3 25 | -3.7% | -2.3% | ||
| Q2 25 | 0.8% | -0.1% | ||
| Q1 25 | -2.0% | -14.3% | ||
| Q4 24 | 8.4% | -121.2% | ||
| Q3 24 | 7.7% | -5.4% | ||
| Q2 24 | 2.8% | -2.3% | ||
| Q1 24 | 1.0% | -17.3% |
每股收益（稀释后）CSGPEXAS
| Q4 25 | $0.12 | $-0.45 | ||
| Q3 25 | $-0.07 | $-0.10 | ||
| Q2 25 | $0.01 | $-0.01 | ||
| Q1 25 | $-0.04 | $-0.54 | ||
| Q4 24 | $0.14 | $-4.69 | ||
| Q3 24 | $0.13 | $-0.21 | ||
| Q2 24 | $0.05 | $-0.09 | ||
| Q1 24 | $0.02 | $-0.60 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.6B | $964.7M |
| 总债务越低越好 | $140.0M | — |
| 股东权益账面价值 | $8.3B | $2.4B |
| 总资产 | $10.5B | $5.9B |
| 负债/权益比越低杠杆越低 | 0.02× | — |
8季度趋势，按日历期对齐
现金及短期投资CSGPEXAS
| Q4 25 | $1.6B | $964.7M | ||
| Q3 25 | $1.9B | $1.0B | ||
| Q2 25 | $3.6B | $858.4M | ||
| Q1 25 | $3.7B | $786.2M | ||
| Q4 24 | $4.7B | $1.0B | ||
| Q3 24 | — | $1.0B | ||
| Q2 24 | — | $946.8M | ||
| Q1 24 | — | $652.1M |
总债务CSGPEXAS
| Q4 25 | $140.0M | — | ||
| Q3 25 | $1.0B | — | ||
| Q2 25 | $1.0B | — | ||
| Q1 25 | $1.0B | — | ||
| Q4 24 | $1.0B | — | ||
| Q3 24 | $1.0B | — | ||
| Q2 24 | $1.0B | — | ||
| Q1 24 | $1.0B | — |
股东权益CSGPEXAS
| Q4 25 | $8.3B | $2.4B | ||
| Q3 25 | $8.6B | $2.5B | ||
| Q2 25 | $8.6B | $2.5B | ||
| Q1 25 | $8.6B | $2.4B | ||
| Q4 24 | $7.6B | $2.4B | ||
| Q3 24 | $7.5B | $3.2B | ||
| Q2 24 | $7.4B | $3.2B | ||
| Q1 24 | $7.3B | $3.1B |
总资产CSGPEXAS
| Q4 25 | $10.5B | $5.9B | ||
| Q3 25 | $10.8B | $5.9B | ||
| Q2 25 | $10.5B | $5.8B | ||
| Q1 25 | $10.4B | $5.7B | ||
| Q4 24 | $9.3B | $5.9B | ||
| Q3 24 | $9.1B | $6.7B | ||
| Q2 24 | $9.1B | $6.7B | ||
| Q1 24 | $9.0B | $6.4B |
负债/权益比CSGPEXAS
| Q4 25 | 0.02× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.13× | — | ||
| Q3 24 | 0.13× | — | ||
| Q2 24 | 0.14× | — | ||
| Q1 24 | 0.14× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $162.1M | $151.7M |
| 自由现金流经营现金流 - 资本支出 | $101.3M | $120.4M |
| 自由现金流率自由现金流/营收 | 11.3% | 13.7% |
| 资本支出强度资本支出/营收 | 6.8% | 3.6% |
| 现金转化率经营现金流/净利润 | 3.49× | — |
| 过去12个月自由现金流最近4个季度 | $123.0M | $356.8M |
8季度趋势，按日历期对齐
经营现金流CSGPEXAS
| Q4 25 | $162.1M | $151.7M | ||
| Q3 25 | $68.2M | $219.9M | ||
| Q2 25 | $146.5M | $89.0M | ||
| Q1 25 | $53.2M | $30.8M | ||
| Q4 24 | $94.6M | $47.1M | ||
| Q3 24 | $100.3M | $138.7M | ||
| Q2 24 | $58.1M | $107.1M | ||
| Q1 24 | $139.6M | $-82.3M |
自由现金流CSGPEXAS
| Q4 25 | $101.3M | $120.4M | ||
| Q3 25 | $-5.5M | $190.0M | ||
| Q2 25 | $27.7M | $46.7M | ||
| Q1 25 | $-500.0K | $-365.0K | ||
| Q4 24 | $25.2M | $10.7M | ||
| Q3 24 | $40.2M | $112.6M | ||
| Q2 24 | $-14.7M | $71.2M | ||
| Q1 24 | $-237.1M | $-120.0M |
自由现金流率CSGPEXAS
| Q4 25 | 11.3% | 13.7% | ||
| Q3 25 | -0.7% | 22.3% | ||
| Q2 25 | 3.5% | 5.8% | ||
| Q1 25 | -0.1% | -0.1% | ||
| Q4 24 | 3.6% | 1.5% | ||
| Q3 24 | 5.8% | 15.9% | ||
| Q2 24 | -2.2% | 10.2% | ||
| Q1 24 | -36.1% | -18.8% |
资本支出强度CSGPEXAS
| Q4 25 | 6.8% | 3.6% | ||
| Q3 25 | 8.8% | 3.5% | ||
| Q2 25 | 15.2% | 5.2% | ||
| Q1 25 | 7.3% | 4.4% | ||
| Q4 24 | 9.8% | 5.1% | ||
| Q3 24 | 8.7% | 3.7% | ||
| Q2 24 | 10.7% | 5.1% | ||
| Q1 24 | 57.4% | 5.9% |
现金转化率CSGPEXAS
| Q4 25 | 3.49× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 23.63× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.58× | — | ||
| Q3 24 | 1.89× | — | ||
| Q2 24 | 3.03× | — | ||
| Q1 24 | 20.84× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CSGP
| Co Star | $503.8M | 56% |
| Other | $283.0M | 31% |
| Loop Net | $94.7M | 11% |
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
